MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

A

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

82.89 1.96

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

81.29

Max

86.1

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.1B

13B

Ankstesnė atidarymo kaina

80.93

Ankstesnė uždarymo kaina

82.89

Naujienos nuotaikos

By Acuity

50%

50%

166 / 372 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-07 23:11; UTC

Uždarbis

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026-01-07 22:55; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026-01-07 21:39; UTC

Pagrindinės rinkos jėgos

Raytheon Down Following Trump Post Criticizing Company

2026-01-07 20:13; UTC

Pagrindinės rinkos jėgos

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026-01-07 20:03; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026-01-07 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-07 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026-01-07 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026-01-07 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026-01-07 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026-01-07 22:48; UTC

Rinkos pokalbiai

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026-01-07 22:46; UTC

Uždarbis

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026-01-07 22:45; UTC

Uždarbis

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026-01-07 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026-01-07 22:42; UTC

Uždarbis

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026-01-07 22:41; UTC

Uždarbis

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026-01-07 22:40; UTC

Pagrindinės rinkos jėgos

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026-01-07 22:31; UTC

Rinkos pokalbiai

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026-01-07 22:22; UTC

Rinkos pokalbiai

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026-01-07 22:01; UTC

Rinkos pokalbiai

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026-01-07 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-07 21:46; UTC

Rinkos pokalbiai

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026-01-07 21:22; UTC

Įsigijimai, susijungimai, perėmimai

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026-01-07 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026-01-07 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026-01-07 20:29; UTC

Įsigijimai, susijungimai, perėmimai

AbbVie Near Deal for Revolution Medicines -- Update

2026-01-07 20:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026-01-07 19:58; UTC

Rinkos pokalbiai

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026-01-07 19:48; UTC

Pagrindinės rinkos jėgos

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

13% į viršų

12 mėnesių prognozė

Vidutinis 92.08 USD  13%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

14

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

166 / 372 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat